Squarepoint’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Squarepoint’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-16,327	Closed	-$54K	–	3630
2021 Q2	$54K	Sell	16,327 -11,588	-42%	-$37.2K	﹤0.01%	3098
2021 Q1	$105K	Buy	27,915 +1,871	+7%	+$8.13K	﹤0.01%	2895
2020 Q4	$92K	Buy	+26,044	New	+$110K	﹤0.01%	2738
2020 Q1	–	Sell	-3,045	Closed	-$39K	–	2712
2019 Q4	$39K	Sell	3,045 -746	-20%	-$6.89K	﹤0.01%	2409
2019 Q3	$40K	Sell	3,791 -5,466	-59%	-$71.4K	﹤0.01%	2257
2019 Q2	$157K	Buy	9,257 +6,958	+303%	+$188K	﹤0.01%	2156
2019 Q1	$77K	Buy	+2,299	New	+$76.8K	﹤0.01%	2058
2018 Q2	–	Sell	-1,089	Closed	-$71K	–	2141
2018 Q1	$71K	Buy	+1,089	New	+$82.2K	﹤0.01%	1598
2017 Q1	–	Sell	-1,079	Closed	-$147K	–	2007
2016 Q4	$147K	Buy	+1,079	New	+$192K	0.01%	1544
2016 Q1	–	Sell	-1,040	Closed	-$211K	–	1516
2015 Q4	$211K	Buy	+1,040	New	+$186K	0.02%	971

Other funds holding BLCM

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIIC

AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return

Squarepoint's BLCM Position: Q3 2021 in Review

Squarepoint sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q3 2021, closing a stake of 16,327 shares — an estimated $54K sold.

Squarepoint first reported a position in BLCM in Q4 2015 and held it in 10 quarters. The position peaked at $211K in Q4 2015. 28 funds tracked by Wall St. Rank hold BLCM as of Q3 2021.

Squarepoint reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
Squarepoint sold 16,327 Bellicum Pharmaceuticals, Inc. shares in Q3 2021, an estimated $54K.
Squarepoint first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2015 and held it in 10 quarters.
Squarepoint's Bellicum Pharmaceuticals, Inc. position peaked at $211K in Q4 2015.
28 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q3 2021.

Based on Squarepoint's 13F filing for Q3 2021, filed 15 Nov 2021.